Study: Fenofibrate is safe for diabetes patients with renal impairment

02/1/2012 |

Data on 9,795 type 2 diabetes patients with at least moderate renal impairment revealed that those who took daily doses of fenofibrate for five years attained an 11% reduction in total cardiovascular events regardless of impairment severity, compared with those who took a placebo. The treatment also did not appear to increase drug-related safety concerns among diabetes patients with moderate renal impairment, compared with those with mild renal impairment, researchers reported in Diabetes Care.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA